• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    Merck KGaA, Quris-AI Expand Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC

    Sartorius, SPARTA Biodiscovery Partner on Nanoparticle Analysis Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    AMERIPHARMA

    Bachem

    U.S. Pharmacopeia (USP)

    Federal Equipment Company

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    AMERIPHARMA

    Bachem

    U.S. Pharmacopeia (USP)

    Federal Equipment Company

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    Biogen

    ...

    Biogen
    07.15.19
    Headquarters: Cambridge, MA
    twitter.com/biogenidec
    www.biogenidec.com


    Headcount: 7,800
    Year Established: 2003
    Revenues:  $13,453  (+10%)
    Net Income:  $4,431  (+75%)
    R&D:  $2,597   (+15%)

    Top Selling Drugs  
    Drug Indication 2018 Sales (+/-%)
    Tecfidera multiple sclerosis $4,274 1%
    Avonex multiple sclerosis $1,915 -11%
    Tysabri multiple sclerosis $1,864 -6%
    Spinraza spinal muscular atrophy $1,724 95%
    Eticovo rheumatoid arthritis $485 31%
    Plegridy multiple sclerosis $448 -9%


    A steady growth trajectory has Biogen up in the rankings this year. In addition to its flagship multiple sclerosis franchise, the continued global launch of spinal muscular atrophy drug Spinraza, which contributed $518 million in revenues in the first quarter, up 42%, is driving growth.

    Biogen continues to diversify its pipeline in neuromuscular diseases and movement disorders, and, with the recent acquisition of Nightstar Therapeutics, specialty ophthalmology. By the end of 2020 the company expect results across its clinical programs in MS, progressive supranuclear palsy, ALS, Parkinson’s, pain, cognitive impairment in schizophrenia, epilepsy, stroke, and lupus.

    In June, Biogen completed the acquisition of Nightstar Therapeutics, a gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders, in a transaction valued at approximately $800 million. Biogen added two mid- to late-stage clinical assets as well as preclinical programs in ophthalmology. NST’s lead asset is NSR-REP1 for the treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder, which leads to blindness and has no approved treatments. NSR-RPGR is NST’s second clinical program for X-linked retinitis pigmentosa, which is also a rare inherited retinal disease with no approved treatments.

    Further investing in its biosimilar business, under an asset transfer deal with its collaboration partner Samsung BioLogics, assets of Samsung Bioepis were transferred to Biogen on November 7th for approximately $677 million. Samsung Bioepis was founded in 2012 as an 85:15 joint venture between Samsung BioLogics and Biogen. Last June Biogen raised its stake in Bioepis, increasing its ownership to 49.9 percent.

    Under the successful alliance, Biogen became the first company in Europe with approved biosimilars referencing the three most prescribed anti-TNF biologic treatments, with the launch of IMRALDI, a biosimilar referencing Abbvie’s Humira.

    After evaluating its manufacturing strategy, in March, Biogen sold its large-scale biologics manufacturing operations in Hillerød, Denmark, to Fujifilm Corp. for up to $890 million. As part of the deal, Fujifilm will use the Hillerød site to produce commercial products for Biogen, such as TYSABRI, and other third-party products.

    In unfortunate R&D news, the discontinuation of aducanumab for Alzheimer’s disease was a big disappointment. Biogen and partner Eisai discontinued global Phase III trials after futility analysis indicated the trials were unlikely to meet their primary endpoint. 

    On the upside, Biogen is a few months away from expanding its MS franchise with Vumerity, which has an FDA target action date in 4Q19. Recent Phase III study results showed Vumerity significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis patients.

    To support research efforts in neurological diseases, an alliance with C4 Therapeutics will investigate the use of C4’s protein degradation platform to develop new treatments for neurological conditions, such as Alzheimer’s and Parkinson’s. Biogen will pay C4 up to $415 million in upfront and potential milestones.      Additionally, Biogen paid $74 million upfront to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using SkySTAR platform, which offers a new approach to target neurological conditions using selective RNA-modulating small molecules. 
    Related Searches
    • license
    • collaboration
    • biosimilar
    • manufacturing operations
    Suggested For You
    Samsung Biologics Samsung Biologics
    Softweb Solutions Softweb Solutions
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    The Top Companies Report The Top Companies Report
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    Skyhawk, Biogen Expand Alliance in Neurological Disorders Skyhawk, Biogen Expand Alliance in Neurological Disorders
    Sierra’s Momelotinib Granted FDA Fast Track Designation Sierra’s Momelotinib Granted FDA Fast Track Designation
    Risk-Based Monitoring Risk-Based Monitoring
    Aclaris Therapeutics Submits IND for RA Treatment Aclaris Therapeutics Submits IND for RA Treatment
    The Orphan Promise The Orphan Promise
    Biogen Completes $800M Nightstar Acquisition Biogen Completes $800M Nightstar Acquisition
    New Drug Development Strategies Needed for Alzheimer’s Treatments New Drug Development Strategies Needed for Alzheimer’s Treatments
    The Manufacturing Revolution In Medicine The Manufacturing Revolution In Medicine
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review

    Related Buyers Guide Companies

    • Samsung Biologics

      Samsung Biologics

      ...
      Minji Kim, Global PR Senior Specialist 12.02.21

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20

    • Trials & Filings
      FDA Accepts RedHill Biopharma’s NDA for Talicia

      FDA Accepts RedHill Biopharma’s NDA for Talicia

      Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
      07.16.19


    • The Top Companies Report

      The Top Companies Report

      Combined sales for 2018 topped the $600 billion mark
      Tim Wright, Editor 07.15.19

    • Trials & Filings
      Syndax Pharma Gets IND Clearance for Leukemia Treatment

      Syndax Pharma Gets IND Clearance for Leukemia Treatment

      Will begin Phase 1/2 trial for targeted Menin inhibitor, SNDX-5613, in patients with relapsed/refractory acute leukemias
      07.11.19

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    • Merck KGaA, Quris-AI Expand Collaboration
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    PLT Health Solutions Granted Claims for Botanical Ingredient in Canada
    CRN Files Petition with FTC For Clarity on Health Products Compliance Guidance
    Vitafoods Europe Relocates to Barcelona Starting 2025
    Coatings World

    Latest Breaking News From Coatings World

    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    AkzoNobel Shares Sustainable Architectural Solutions at Conference
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
    Siemens Healthineers’ Magnetom Viato.Mobile Cleared by FDA
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treat
    Sanner Group Opens Second Manufacturing Facility in China
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Stoelzle Glass Group Names New CEO
    Happi

    Latest Breaking News From Happi

    Breakfast with Oral Care Benefits?
    Stanford Researchers Study Skin and Sensorial Perception
    L’Oréal Awarded US Patent for Makeup
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Climate Targets Validated by SBTi
    ROSS Offering Cost-Effective, Expertly Reconditioned Equipment
    Amcor plc Adds Lucrèce Foufopoulos-De Ridder to Board of Directors
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Centinel Spine prodisc System Surpasses 2,500-Implant Milestone
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More
    SCHOTT Strengthens Glass Substrate Portfolio

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login